Top Reasons to Invest in Biotech Today

May 22, 2024

Announcing the Innovative, New, Non-Equity…

FLASH-CASH OPTIONS
Making People “In-the-Know” Very Rich!

My name’s Chris Verhaegh and Flash-Cash Options is creating the biggest wave of “behind the scenes” activity I’ve seen in 40 years as a trading professional.

According to the OCC (Option Clearing Corp.), Institutional Traders drove the volume on these non-equity options up 33% in the past year alone!

Yet, most retail traders, like you, still don’t even know they exist.

And I think that’s a real shame; because you get 9 Unique Profit Enhancing Benefits when trading Flash-Cash Options that you don’t get trading regular options.

Click Here and discover how you can enjoy greater safety… profitability… and pure trading fun with Flash-Cash Options.

Top Reasons to Invest in Biotech Today by Ian Cooper

Keeping Trade Records by Andy Chambers

PULSE Options Weekly Newsletter by Chris Verhaegh

TradeWins Author Team

Unlock the 30-day secret to potentially making an extra $1,403 per month with a tiny account!

In fact, You could’ve made a total of 742% on your money doing exactly this the past 5 years (includes winners and losers).

What if you could make an extra $1,403 every 30 days?

You’re not getting rich, per se…

But you’re generating some extra cash to have and spend during these unprecedented economic times.

Now, that $1,403 isn’t a promise… it’s simply an average.

As you’re about to see… with many opportunities, you could’ve had months where you turned a few hundred bucks into thousands and thousands.

You don’t need any special skills.

Just patience and trust in a system that’s worked for years. My system.

Inside Trading Newsletter

Subscription Services

E-Books

Customer Satisfaction Survey 2020

Top Reasons to Invest in Biotech Today
by Ian Cooper

Biotech stocks offer some of the most explosive opportunities.

That is, if you spot the right ones.

For example, some the hottest ideas can be found in weight loss drugs, cancer treatments known as ADCs (antibody-drug conjugates), and in gene-editing.

Look at CRISPR Therapeutics (CRSP), for example. Not long ago, it received US FDA approval for its gene-editing therapy for sickle cell disease and transfusion-dependent beta-thalassemia, a genetic disorder that prevents the production of hemoglobin in the blood and requires regular blood transfusions.

With that news, we watched CRISPR jump from about $40 to $70.

Or, look at Eli Lilly (LLY). Thanks to strong demand for obesity medication, the stock popped from about $580 to $760, and it’s still moving higher.

Of course, there are many more. But you get the point.

What makes biotech even hotter is that major drug companies are on a shopping spree.

Over the next few years, drug giants could lose billions to patent expirations. According to EY analysts, the top 20 giants could lose about $180 billion in sales by the end of the decade. To stop some of the potential bloodshed, companies are building up their pipelines, bring in fresh new drugs with multi-billion-dollar potential. For example, most recently, Johnson & Johnson said it would acquire Ambrx Biopharma for $2 billion. Pfizer acquired Seagen for $43 billion.

Keeping Trade Records
by Andy Chambers

Proper record keeping is another one of those basic, fundamental activities that should become second nature to you. There are three sets of records you should always keep up to date.

- Individual Trade Tickets
- Trading Log
- Open Order Log

Individual Trade Tickets

A trade ticket is a paper record of every order placed and it should be completed by hand before any order is entered. Computers can crash, brokerage firms can make mistakes, and traders often enter orders incorrectly. By writing a legible order ticket for each trade you can help eliminate, or at least reduce sharply, the incidence of trader order entry error. You will also have a complete record for each and every market action you take.

At the top of the trade ticket enter the name of the brokerage firm receiving the order, your account number, and the order date. Complete these three sections even if you have only one trading account now. You may have another account in the future and a completed ticket will help you to identify exactly where and when you placed an order. It is also a good idea to number your tickets sequentially.

First Things First

The Economic Calendar shows there are number of FOMC Members Speaking this upcoming week. The Market will be listening intently as they are looking for clues as to what the Fed might do in the upcoming months.

But this upcoming week will focus less on the spoken word and more so on what’s written. The Market will be focusing their attention on Wednesday’s FOMC Meeting Minutes Release.

Everyone is looking for clues on when the Fed might first lower Short-Term Interest Rates. As you can see by the table below, it looks like September.

As far Earnings this upcoming week, the only one that looks to stand out to me will be Wednesday’s Nvidia (NVDA) Announcement. That’s not saying the others are tradable, but I’m looking more along the lines of being able to move the market as a whole.

www.tradewins.com

© Copyright 2024 TradeWins.com. All rights reserved.
TradeWins Publishing, 22C New Leicester Hwy, #117, Asheville, NC 28806
Email: support@iss-trading.com | Phone: 888-233-1431 | Fax: 888-258-4938

PLEASE READ: Auto-trading, or any broker or advisor-directed type of trading, is not supported or endorsed by TradeWins. For additional information on auto-trading, you may visit the SEC’s website: All About Auto-Trading, TradeWins does not recommend or refer subscribers to broker-dealers. You should perform your own due diligence with respect to satisfactory broker-dealers and whether to open a brokerage account. You should always consult with your own professional advisers regarding equities and options on equities trading.

1) The information provided by the newsletters, trading, training and educational products related to various markets (collectively referred to as the “Services”) is not customized or personalized to any particular risk profile or tolerance. Nor is the information published by TradeWins Publishing (“TradeWins”) a customized or personalized recommendation to buy, sell, hold, or invest in particular financial products. The Services are intended to supplement your own research and analysis.

2) TradeWins’ Services are not a solicitation or offer to buy or sell any financial products, and the Services are not intended to provide money management advice or services.

3) Past performance is not necessarily indicative of future results. Trading and investing involve substantial risk. Trading on margin carries a high level of risk, and may not be suitable for all investors. Other than the refund policy detailed elsewhere, TradeWins does not make any guarantee or other promise as to any results that may be obtained from using the Services. No person subscribing for the Services (“Subscriber”) should make any investment decision without first consulting his or her own personal financial adviser, broker or consultant. TradeWins disclaims any and all liability in the event anything contained in the Services proves to be inaccurate, incomplete or unreliable, or results in any investment or other loss by a Subscriber.

4) You should trade or invest only “risk capital” – money you can afford to lose. Trading stocks and stock options involves high risk and you can lose the entire principal amount invested or more.

5) All investments carry risk and all trading decisions made by a person remain the responsibility of that person. There is no guarantee that systems, indicators, or trading signals will result in profits or that they will not produce losses. Subscribers should fully understand all risks associated with any kind of trading or investing before engaging in such activities.

6) Some profit examples are based on hypothetical or simulated trading. This means the trades are not actual trades and instead are hypothetical trades based on real market prices at the time the recommendation is disseminated. No actual money is invested, nor are any trades executed. Hypothetical or simulated performance is not necessarily indicative of future results. Hypothetical performance results have many inherent limitations, some of which are described below. Also, the hypothetical results do not include the costs of subscriptions, commissions, or other fees. Because the trades underlying these examples have not actually been executed, the results may understate or overstate the impact of certain market factors, such as lack of liquidity. Simulated trading services in general are also designed with the benefit of hindsight, which may not be relevant to actual trading. In addition, hypothetical trading does not involve financial risk, and no hypothetical trading record can completely account for the impact of financial risk of actual trading. TradeWins makes no representations or warranties that any account will or is likely to achieve profits similar to those shown.

7) No representation is being made that you will achieve profits or the same results as any person providing testimonial. No representation is being made that any person providing a testimonial is likely to continue to experience profitable trading after the date on which the testimonial was provided, and in fact the person providing the testimonial may have experienced losses.

8) The author experiences are not typical. The author is an experienced investor and your results will vary depending on risk tolerance, amount of risk capital utilized, size of trading position and other factors. Certain Subscribers may modify the author methods, or modify or ignore the rules or risk parameters, and any such actions are taken entirely at the Subscriber’s own election and for the Subscriber’s own risk.

If you wish to stop receiving our emails or change your subscription options, please Manage Your Subscription
TradeWins Publishing, 528 North Country Rd., St. James, NY 11780